Launched within the InnoCentive crowdsourcing innovation platform, the challenge seeks to identify a single-source mRNA vaccine that can provide the same level of COVID-19 protection as approved multidose vaccines, according to the company. The competition includes participants from various backgrounds, including science, engineering, and technology.

To participate, a written proposal must be submitted directly via the InnoCentive platform by the end of May. The winning proposal will be awarded a monetary prize and be acquired by Debiopharm for further development.

More information can be found on the challenge's website.

Debiopharm, Genome & Company collaborate on antibody-drug conjugates
Debiopharm and Genome & Company announced a plan to collaborate on developing antibody-drug conjugate oncology therapies.

Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...